<DOC>
	<DOC>NCT01474668</DOC>
	<brief_summary>This study will be an open-label, non-randomized, absorption, metabolism, and excretion study of [14C]-GDC 0941 administered as an oral dose to 6 healthy male subjects following at least a 10-hour fast from food (not including water).</brief_summary>
	<brief_title>Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Within BMI range 18.5 to 29.9 kg/m2, inclusive In good health, determined by no clinically significant findings from medical history, 12lead ECG, and vital signs Clinical laboratory evaluations within the reference range for the test laboratory Negative test for selected drugs of abuse at Screening and at Checkin Negative hepatitis panel (including hepatitis B surface antigen [HBsAg], hepatitis C virus antibody [antiHCV]) and negative HIV antibody screens Subjects will either be sterile or agree to use an approved form of contraception from Checkin until 45 days following Study Completion/ET Agree not to donate sperm from Screening throughout the study period and for at least 3 months (90 days) after the last dose of study drug A minimum of 1 to 2 bowel movements per day Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (except that appendectomy and hernia repair will be allowed) History of Gilbert's Syndrome History of diabetes mellitus and/or elevated fasting glucose at baseline History or presence of an abnormal ECG History of alcoholism or drug addiction within 1 year prior to Checkin Participation in more than one other radiolabeled investigational study drug trial within 12 months prior to Checkin. The previous radiolabeled study drug must have been received more than 6 months prior to Checkin for this study and the total exposure from this study and the previous study will be within the recommended levels considered safe Exposure to significant radiation within 12 months prior to Checkin Use of any tobaccocontaining or nicotinecontaining products within 6 months prior to Checkin or positive urine drug screen for cotinine Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 halflives or 30 days, whichever is longer, prior to Checkin Use of any prescription medications/products within 14 days prior to Checkin, unless deemed acceptable by the Investigator Use of any overthecounter (OTC), nonprescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations) within 7 days prior to Checkin Use of alcohol, grapefruit, or caffeinecontaining foods or beverages within 72 hours prior to Checkin, unless deemed acceptable by the Investigator Poor peripheral venous access Donation of blood from 30 days prior to Screening or of plasma from 2 weeks prior to Screening Receipt of blood products within 2 months prior to Checkin Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>